Results 11 to 20 of about 3,442,924 (154)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. [PDF]

Oncol Rep, 2022
Neurofibromin 1 (NF1) is a tumor suppressor that has been previously reported to regulate RAS-MAPK signaling. The present study investigated the possible relationship between NF1 expression and anti-EGFR antibody (cetuximab) sensitivity in colorectal ...
Tak E, Kim M, Cho Y, Choi S, Kim J, Han B, Kim HD, Jang CS, Kim JE, Hong YS, Kim SY, Kim TW.   +11 more
europepmc   +5 more sources

Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer. [PDF]

Cell Mol Life Sci
Although amplifications and mutations in receptor tyrosine kinases (RTKs) act as bona fide oncogenes, in most cancers, RTKs maintain moderate expression and remain wild-type.
Jones VT, Graves-Deal R, Cao Z, Bogatcheva G, Ramirez MA, Harmych SJ, Higginbotham JN, Sharma V, Damalanka VC, Wahoski CC, Joshi N, Irudayam MJ, Roland JT, Ayers GD, Liu Q, Coffey RJ, Janetka JW, Singh B.   +17 more
europepmc   +5 more sources

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer [PDF]

Acta Biochimica et Biophysica Sinica, 2023
The emergence of anti-EGFR therapy has revolutionized the treatment of colorectal cancer (CRC). However, not all patients respond consistently well.
Yuan Yitao, Sun Xun, Liu Mengling, Li Suyao, Dong Yu, Hu Keshu, Zhang Jiayu, Xu Bei, Ma Sining, Jiang Hesheng, Hou Pengcong, Lin Yufu, Gan Lu, Liu Tianshu   +13 more
doaj   +3 more sources

PRSS contributes to cetuximab resistance in colorectal cancer. [PDF]

Sci Adv, 2020
PRSS leads to cetuximab resistance by cleaving the drug, and SPINK1 or modified mAbs can avoid PRSS cleavage. Cetuximab improves the survival of patients with metastatic colorectal cancer.
Tan Z, Gao L, Wang Y, Yin H, Xi Y, Wu X, Shao Y, Qiu W, Du P, Shen W, Fu L, Jia R, Zhao C, Zhang Y, Zhao Z, Sun Z, Chen H, Hu X, Xu J, Xu J, Wang Y.   +20 more
europepmc   +5 more sources

MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3. [PDF]

Cancer Biol Ther
Despite advances in targeted therapies, primary and acquired resistance make the treatment of colorectal cancer (CRC) a pressing issue to be resolved. According to reports, the development of CRC is linked to miRNA dysregulation.
Peng C, Li X, Yao Y, Nie Y, Fan L, Zhu C.   +5 more
europepmc   +5 more sources

BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. [PDF]

Cancer Res, 2018
Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and acquired resistance. We and others have demonstrated that cetuximab resistance in HNSCC
Leonard B, Brand TM, O'Keefe RA, Lee ED, Zeng Y, Kemmer JD, Li H, Grandis JR, Bhola NE.   +8 more
europepmc   +7 more sources

3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis. [PDF]

Cancer Gene Ther, 2023
Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide. Cetuximab, in combination with chemotherapy, is effective for treating patients with wild-type KRAS/BRAF metastatic CRC (mCRC).
Mu M, Zhang Q, Zhao C, Li X, Chen Z, Sun X, Yu J.   +6 more
europepmc   +2 more sources

IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m⁶A-dependent manner. [PDF]

Cell Death Dis, 2023
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), an RNA-binding protein, is associated with tumorigenesis and progression. However, the exact molecular mechanisms of IGF2BP3 in colorectal cancer (CRC) oncogenesis, progression, and drug ...
Chen LJ, Liu HY, Xiao ZY, Qiu T, Zhang D, Zhang LJ, Han FY, Chen GJ, Xu XM, Zhu JH, Ding YQ, Wang SY, Wang SY, Ye YP, Jiao HL.   +14 more
europepmc   +2 more sources

Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO-Mediated Tryptophan Metabolism. [PDF]

Cancer Sci
Primary or acquired mutations in RAS/RAF genes resulting in cetuximab resistance have limited its clinical application in colorectal cancer (CRC) patients. The mechanism of this resistance remains unclear.
Zhou Y, Tao Q, Luo C, Chen J, Chen G, Sun J.   +5 more
europepmc   +2 more sources

Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression. [PDF]

Exp Ther Med, 2023
The anti-EGFR antibody cetuximab is used as a first-line targeted therapeutic drug in colorectal cancer. It has previously been reported that the efficacy of the EGFR antibody cetuximab is limited by the emergence of acquired drug resistance.
Wei Z, Wang Z, Chai Q, Li Z, Zhang M, Zhang Y, Zhang L, Tang Q, Zhu H, Sui H.   +9 more
europepmc   +2 more sources